# Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

> **NCT06176885** · PHASE2 · RECRUITING · sponsor: **yue junhan** · enrollment: 36 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT06176885
- **Lead sponsor:** yue junhan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2025-12-20
- **Final completion:** 2026-12-20
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176885, "Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06176885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*